a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. Int J Cancer. 2016;139(10):2336-2342.
[11]Tarantino P, Viale G, Press MF, et al. ESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Annals of Oncology (2023). [12]Curigliano G, Castelo-Branco L, G...
human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). 2024 ASCO. LBA
11.Tarantino P,et al.ESMO expert consensus statements(ECS)on the definition,diagnosis,and management of HER2-low breast cancer.Ann Oncol.2023 Aug;34(8):645-659.Narayan P,et al.Journal of Clinical Oncology,2023,41(11):2108-2116. 12.Garrido C,et al.Analytical and clinical validation of PAT...
ESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Paolo Tarantino, Giuseppe Viale, Michael F. Press, Xichun Hu, Frederique Penault Llorca, Aditya Bardia, Anna Batistatou, Harold J. Burstein, Li...
[1]Tarantino P, Viale G, Press MF, Hu X, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023;34:645–59.[2]Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis...
Breast cancer has been traditionally classified as either human epidermal growth factor receptor 2 (HER2)-positive or HER2-negative based on immunohistoche
5. Tarantino P, Viale G, Press MF, et al. ESMO expert consensus statements(ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol.2023 Aug;34(8):645-659. *本材料由阿斯利康提供,仅供医疗卫生专业人士参考 ...
This article will review the definition of HER2-low breast cancer, the progress of drug therapy such as ADC, and the current challenges faced by this subgroup.孜拉兰·玉山江祖丽皮耶·买合木提何沐钊李鸿涛Cancer Research on Prevention & Treatment...
Approximately one in five breast cancers are driven by amplification and overexpression of the human epidermal growth factor receptor 2 (HER2) receptor kinase, and HER2-enriched (HER2E) is one of four major transcriptional subtypes of breast cancer. We set out to understand the genomics of HER2 ...